Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir.

Patel, Mira C; Chesnokov, Anton; Jones, Joyce; Mishin, Vasiliy P; De La Cruz, Juan A; Nguyen, Ha T; Zanders, Natosha; Wentworth, David E; Davis, Todd C; Gubareva, Larisa V

Patel, Mira C; Chesnokov, Anton; Jones, Joyce; Mishin, Vasiliy P; De La Cruz, Juan A; Nguyen, Ha T; Zanders, Natosha; Wentworth, David E; Davis, Todd C; Gubareva, Larisa V.

Afiliação

Patel MC; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Chesnokov A; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jones J; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Mishin VP; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
De La Cruz JA; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Nguyen HT; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; General Dynamics Information Technology, Atlanta, GA, USA.
Zanders N; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; General Dynamics Information Technology, Atlanta, GA, USA.
Wentworth DE; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Davis TC; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Gubareva LV; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: lgubareva@cdc.gov.

Antiviral Res ; 188: 105035, 2021 04.

Article em En | MEDLINE | ID: mdl-33581212

Assuntos

Antivirais/farmacologia; Vírus da Influenza A/efeitos dos fármacos; Piridinas/farmacologia; Pirimidinas/farmacologia; Pirróis/farmacologia; RNA Polimerase Dependente de RNA/antagonistas & inibidores; Proteínas Virais/antagonistas & inibidores; Animais; Farmacorresistência Viral; Inibidores Enzimáticos/farmacologia; Humanos; Vírus da Influenza A Subtipo H1N1/efeitos dos fármacos; Vírus da Influenza A Subtipo H1N1/genética; Vírus da Influenza A Subtipo H3N2/efeitos dos fármacos; Vírus da Influenza A Subtipo H3N2/genética; Subtipo H7N9 do Vírus da Influenza A/efeitos dos fármacos; Subtipo H7N9 do Vírus da Influenza A/genética; Vírus da Influenza A/genética; Influenza Humana/virologia; Testes de Sensibilidade Microbiana; Infecções por Orthomyxoviridae/virologia; RNA Polimerase Dependente de RNA/genética; Proteínas Virais/genética; Replicação Viral/efeitos dos fármacos

Palavras-chave

Drug susceptibility; H7N9; PB2 inhibitor; Pandemic potential; Pimodivir; Zoonotic influenza

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Vírus da Influenza A / Piridinas / Pirimidinas / Pirróis / Proteínas Virais / RNA Polimerase Dependente de RNA Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Antiviral Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google